Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice
Clinical Infectious Diseases · 15.12.2023 · 77 (12) · 1626-1634
DOI: 10.1093/cid/ciad460 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 09.08.2023. Verfasst von Essy Mozaffari und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Foster City, California, USA. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Background
Immunocompromised patients are at high risk of severe coronavirus disease 2019 (COVID-19) and death, yet treatment strategies for immunocompromised patients hospitalized for COVID-19 reflect variations in clinical practice. In this comparative effectiveness study, we investigated the effect of remdesivir treatment on inpatient mortality among immunocompromised patients hospitalized for COVID-19 across all variants of concern (VOC) periods.
Methods
Data for immunocompromised patients hospitalized for COVID-19 between December 2020 and April 2022 were extracted from the US PINC AITM Healthcare Database. Patients who received remdesivir within 2 days of hospitalization were matched 1:1 using propensity score matching to patients who did not receive remdesivir. Additional matching criteria included admission month, age group, and hospital. Cox proportional hazards models were used to examine the effect of remdesivir on risk of 14- and 28-day mortality during VOC periods.
Results
A total of 19 184 remdesivir patients were matched to 11 213 non-remdesivir patients. Overall, 11.1% and 17.7% of remdesivir patients died within 14 and 28 days, respectively, compared with 15.4% and 22.4% of non-remdesivir patients. Remdesivir was associated with a reduction in mortality at 14 (hazard ratio [HR], 0.70; 95% confidence interval, .62–.78) and 28 days (HR, 0.75; 95% CI, .68–.83). The survival benefit remained significant during the pre-Delta, Delta, and Omicron periods.
Conclusions
Prompt initiation of remdesivir in immunocompromised patients hospitalized for COVID-19 is associated with significant survival benefit across all variant waves. These findings provide much-needed evidence relating to the effectiveness of a foundational treatment for hospitalized COVID-19 patients among a high-risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gilead Sciences, Foster City, California, USA.
- Certara, New York, New York, USA.
- Baylor University Medical Center, Dallas, Texas, USA.
- Baylor Scott & White Heart and Vascular Hospital, Dallas, Texas, USA.
- Baylor Scott & White The Heart Hospital, Plano, Texas, USA.
- Baylor Scott & White Research Institute, Dallas, Texas, USA.
ORCID-Profile: Andre C Kalil
Förderung
- Gilead Sciences
Zitieren
APA
Mozaffari, E., Chandak, A., Gottlieb, R. L., Chima-Melton, C., Read, S. H., Jiang, H., Chiang, M., Lee, E., Gupta, R., Berry, M., & Kalil, A. C. (2023). Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice. Clinical Infectious Diseases, 77(12), 1626-1634. https://doi.org/10.1093/cid/ciad460
Vancouver
Mozaffari E, Chandak A, Gottlieb RL, Chima-Melton C, Read SH, Jiang H, et al. Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice. Clinical Infectious Diseases. 2023;77(12):1626-1634. doi:10.1093/cid/ciad460
BibTeX
@article{Mozaffari2023,
author = {Mozaffari, Essy and Chandak, Aastha and Gottlieb, Robert L and Chima-Melton, Chidinma and Read, Stephanie H and Jiang, Heng and Chiang, Mel and Lee, EunYoung and Gupta, Rikisha and Berry, Mark and Kalil, Andre C},
title = {Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {77},
number = {12},
pages = {1626--1634},
doi = {10.1093/cid/ciad460}
}
EUVIMED